FI971685L - Takykiniini-antagonisteja - Google Patents
Takykiniini-antagonisteja Download PDFInfo
- Publication number
- FI971685L FI971685L FI971685A FI971685A FI971685L FI 971685 L FI971685 L FI 971685L FI 971685 A FI971685 A FI 971685A FI 971685 A FI971685 A FI 971685A FI 971685 L FI971685 L FI 971685L
- Authority
- FI
- Finland
- Prior art keywords
- tachykinin antagonists
- tachykinin
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9425085.9A GB9425085D0 (en) | 1994-12-13 | 1994-12-13 | Organic compounds |
| GBGB9426016.3A GB9426016D0 (en) | 1994-12-22 | 1994-12-22 | Organic compounds |
| PCT/EP1995/004910 WO1996018643A1 (en) | 1994-12-13 | 1995-12-12 | Tachykinin antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI971685A0 FI971685A0 (fi) | 1997-04-18 |
| FI971685L true FI971685L (fi) | 1997-08-13 |
| FI971685A7 FI971685A7 (fi) | 1997-08-13 |
Family
ID=26306161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI971685A FI971685A7 (fi) | 1994-12-13 | 1995-12-12 | Takykiniini-antagonisteja |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0797583A1 (fi) |
| JP (1) | JPH10511935A (fi) |
| AR (1) | AR001332A1 (fi) |
| AU (1) | AU4343796A (fi) |
| BR (1) | BR9509997A (fi) |
| CA (1) | CA2204130A1 (fi) |
| CO (1) | CO4700289A1 (fi) |
| CZ (1) | CZ179097A3 (fi) |
| FI (1) | FI971685A7 (fi) |
| HU (1) | HUT77002A (fi) |
| IL (1) | IL116323A0 (fi) |
| NO (1) | NO972526L (fi) |
| PE (1) | PE38997A1 (fi) |
| PL (1) | PL320217A1 (fi) |
| SK (1) | SK74697A3 (fi) |
| TR (1) | TR199501568A2 (fi) |
| WO (1) | WO1996018643A1 (fi) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE333879T1 (de) * | 1996-10-07 | 2006-08-15 | Merck Sharp & Dohme | Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| EP1158996A4 (en) | 1999-02-18 | 2005-01-12 | Kaken Pharma Co Ltd | NEW AMIDE SECRETAGOGUES OF GROWTH HORMONE DERIVATIVES |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| KR100885986B1 (ko) | 1999-11-03 | 2009-03-03 | 에이엠알 테크놀로지, 인크. | 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도 |
| CA2415532C (en) | 2000-07-11 | 2010-05-11 | Albany Molecular Research, Inc. | Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof |
| KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
| ZA200800440B (en) | 2005-07-15 | 2009-12-30 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP2805945B1 (en) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
| JP2010516734A (ja) | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物 |
| US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
| US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| KR20100126467A (ko) | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| KR101830447B1 (ko) | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도 |
| CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
| EP2488028B1 (en) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2699568A1 (en) | 2011-04-21 | 2014-02-26 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2844261B1 (en) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| CN105050598B (zh) | 2012-09-28 | 2018-04-27 | 默沙东公司 | 作为erk抑制剂的新型化合物 |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| JPH05186498A (ja) * | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
-
1995
- 1995-12-11 PE PE1995286859A patent/PE38997A1/es not_active Application Discontinuation
- 1995-12-11 IL IL11632395A patent/IL116323A0/xx unknown
- 1995-12-12 JP JP8518261A patent/JPH10511935A/ja active Pending
- 1995-12-12 CA CA002204130A patent/CA2204130A1/en not_active Abandoned
- 1995-12-12 WO PCT/EP1995/004910 patent/WO1996018643A1/en not_active Ceased
- 1995-12-12 CZ CZ971790A patent/CZ179097A3/cs unknown
- 1995-12-12 CO CO95058767A patent/CO4700289A1/es unknown
- 1995-12-12 HU HU9701897A patent/HUT77002A/hu unknown
- 1995-12-12 FI FI971685A patent/FI971685A7/fi not_active Application Discontinuation
- 1995-12-12 EP EP95942131A patent/EP0797583A1/en not_active Withdrawn
- 1995-12-12 BR BR9509997A patent/BR9509997A/pt not_active Application Discontinuation
- 1995-12-12 SK SK746-97A patent/SK74697A3/sk unknown
- 1995-12-12 PL PL95320217A patent/PL320217A1/xx unknown
- 1995-12-12 AU AU43437/96A patent/AU4343796A/en not_active Abandoned
- 1995-12-13 TR TR95/01568A patent/TR199501568A2/xx unknown
- 1995-12-13 AR AR33458995A patent/AR001332A1/es unknown
-
1997
- 1997-06-03 NO NO972526A patent/NO972526L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ179097A3 (en) | 1997-10-15 |
| WO1996018643A1 (en) | 1996-06-20 |
| EP0797583A1 (en) | 1997-10-01 |
| BR9509997A (pt) | 1997-12-30 |
| AR001332A1 (es) | 1997-10-22 |
| HUT77002A (hu) | 1998-03-02 |
| AU4343796A (en) | 1996-07-03 |
| IL116323A0 (en) | 1996-03-31 |
| CA2204130A1 (en) | 1996-06-20 |
| TR199501568A2 (tr) | 1996-07-21 |
| NO972526D0 (no) | 1997-06-03 |
| FI971685A0 (fi) | 1997-04-18 |
| MX9703957A (es) | 1997-09-30 |
| PL320217A1 (en) | 1997-09-15 |
| CO4700289A1 (es) | 1998-12-29 |
| SK74697A3 (en) | 1997-11-05 |
| JPH10511935A (ja) | 1998-11-17 |
| FI971685A7 (fi) | 1997-08-13 |
| NO972526L (no) | 1997-06-03 |
| PE38997A1 (es) | 1997-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI971685A0 (fi) | Takykiniini-antagonisteja | |
| EE9600186A (et) | Neurokiniini (tahhüülkiniini) antagonistid | |
| FI970523A7 (fi) | (Atsetidin-1-yylialkyyli)laktaamit takykiniiniantagonisteina | |
| FI955258L (fi) | Takykiniiniantagonisteina käyttökelpoisia substituoituja pyrrolidiini-3-yl-alkyyli-piperidiineja | |
| NO951613D0 (no) | Ikke-peptidyl tachykinin reseptorantagonister | |
| FI970107L (fi) | Heterosyklisiä takykiniinireseptoriantagonisteja | |
| DK0738150T3 (da) | Bicykliske fibrinogene antagonister | |
| FI946140L (fi) | Diatsabisyklisiä neurokiniiniantagonisteja | |
| DE69719354D1 (de) | Muscarin-antagonisten | |
| FI954008A7 (fi) | Substituoituja bifenyyli-isoksatsolisulfoniamideja | |
| FI951908A7 (fi) | Substituoituja pyridyylipyratsoleja | |
| FI955927A0 (fi) | Substituoidut 1H-imidatsolit | |
| DE69534718D1 (de) | Substituierte 9-alkyladenine | |
| DK0824098T3 (da) | 4-Hydroxy-piperidinderivater | |
| FI960516A7 (fi) | Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja | |
| ATE232526T1 (de) | 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten | |
| NO179550C (no) | Tachykinin reseptorantagonister | |
| DE69735811D1 (de) | Piperazinoderivate als neurokinin-antagonisten | |
| ATE290546T1 (de) | Tachykinin antagoniste | |
| NO975541D0 (no) | 4-hydroksy-piperidinderivater | |
| BR9509559A (pt) | Azolilulsolfonilfeniluracilas substituídas | |
| FI965116L (fi) | Uusia opioidipeptidiantagonisteja | |
| KR970702876A (ko) | 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists) | |
| KR950027351U (ko) | 반목 항타장치 | |
| DK0964867T3 (da) | Tachykininantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application lapsed |